RIGL
NASDAQ
$39.67
Rigel Pharmaceuticals (RIGL)
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat blood disorders, cancer, and rare immune diseases. The company is headquartered in South San Francisco, California.
Sector:
Healthcare
Industry:
Biotechnology
Buy
Target: $54.20 (+36.63%)
Market Cap
$758M
P/E Ratio
6.87
Free Cash Flow Yield
10.46%
Beta (5Y)
1.10
Price Chart
Valuation
Market Cap$758M
P/E6.87
Forward P/E9.01
P/S2.54
P/B1.91
Profitability
Total Revenue (TTM)$300M
Gross Profit (TTM)$243M
EBITDA$127M
Profit Margin14.7%
Operating Margin20.2%
EPS$5.99
Financial Health
Debt-to-Equity11.3%
Free Cash Flow Yield10.46%
Growth & Risk
Revenue 5Y CAGR+17.49%
Beta (5Y)1.10
Sharpe Ratio1.34